The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?

Ther Adv Hematol · 2022 · PMC9310330 · PMID 35898435

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.076so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

The median EFS showed a trend toward improvement with AZA plus pevonedistat (21.0 months versus 16.6 months, respectively) though also did not reach statistical significance ( p = 0.076).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.